
GERMANY - Merck launches strategic venture capital fund
Merck KGaA has launched Merck Serono Ventures, a venture capital fund designed to invest in biotech start-up companies in the company's core therapeutic areas.
Darmstadt-headquartered Merck is a global pharmaceutical and chemical company with annual revenues of EUR 7.6bn. The business has 32,800 employees based in 59 countries.
Merck Serono Ventures' has an initial commitment to invest up to EUR 40m during the next five years. The fund will be included in the company's portfolio development function and closely linked to the Research & Development organization. Particular areas of interest include neurodegenerative diseases, oncology and autoimmune & inflammatory diseases.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater